Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is AIGH Capital Management LLC’s 10th Largest Position

AIGH Capital Management LLC grew its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 9.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 224,713 shares of the company’s stock after buying an additional 20,300 shares during the quarter. Tarsus Pharmaceuticals makes up about 3.9% of AIGH Capital Management LLC’s portfolio, making the stock its 10th largest holding. AIGH Capital Management LLC’s holdings in Tarsus Pharmaceuticals were worth $12,442,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Intech Investment Management LLC purchased a new position in Tarsus Pharmaceuticals during the third quarter worth approximately $282,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 10.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 290,009 shares of the company’s stock worth $9,538,000 after acquiring an additional 28,130 shares during the period. FMR LLC boosted its position in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after acquiring an additional 3,537 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Tarsus Pharmaceuticals by 10.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,835 shares of the company’s stock valued at $1,935,000 after purchasing an additional 5,709 shares during the period. Finally, Verition Fund Management LLC acquired a new stake in Tarsus Pharmaceuticals during the third quarter worth about $763,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Barclays cut their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Oppenheimer increased their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $63.67.

Insider Transactions at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 3,341 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the completion of the transaction, the general counsel now directly owns 58,057 shares of the company’s stock, valued at approximately $2,687,458.53. The trade was a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bobak R. Azamian sold 8,534 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $427,638.74. Following the completion of the sale, the chief executive officer now directly owns 53,635 shares in the company, valued at approximately $2,687,649.85. This trade represents a 13.73 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Stock Performance

Shares of Tarsus Pharmaceuticals stock opened at $51.74 on Friday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -13.58 and a beta of 1.05. The business has a 50-day moving average of $49.00 and a 200 day moving average of $46.10. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. The firm had revenue of $66.41 million during the quarter, compared to analysts’ expectations of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. As a group, sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.